Figure 3.

Anti-tumor Effect of VEGF-siRNA Dry Powder in B16F10 Lung Metastasis Model

Mice with lung metastases were treated with VEGF-siRNA dry powder (n = 6), non-target siRNA dry powder (n = 5), or PBS (n = 5) by intratracheal administration on days 4 and 11. (A and B) The number of tumor nodules on the lung surface was counted 18 days after injection of B16F10 cells. Bars denote the median values. (C and D) H&E-stained sections from each mouse treated with VEGF-siRNA, non-target siRNA, or PBS were randomly selected, and the ratio of tumor/whole-lung tissue area (%) was calculated using an image-analyzing system. p was determined using the Wilcoxon rank-sum test. *p < 0.05, **p < 0.01 between two groups. N.S., not significant.